Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial
Authors' conclusion
The neostigmine infusion modulates the ChAP by potentiating the acetylcholine release leading to reduced systemic inflammation and decreased cytokine levels in septic shock patients.
Study context
- Population
- Adults with septic shock in one ICU of a tertiary academic institution
- Comparison
- Neostigmine infusion 0.2 mg/hr for 5 days vs placebo
- Primary endpoint
- Decrease in tumor necrosis factor-alpha levels
Methodological detailssingle-centre, prospective, double-blinded, placebo-controlled
- Single-centre
- Prospective
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
Tumor necrosis factor-alpha level · day 5
P = 0.002
Secondary outcomes
28-day mortality
P = 0.02
SOFA score change, day 1 to day 5
- Significant reduction in SOFA scores from day 1 to day 5
- P < 0.001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial. Crit Care Med. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →